相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
Jordi Bruix et al.
GASTROENTEROLOGY (2011)
QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
A. Lok et al.
JOURNAL OF HEPATOLOGY (2011)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2011)
HEPATITIS IN 2010 The dawn of a new era in HCV therapy
Sandra Ciesek et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b A Randomized Trial
Donald M. Jensen et al.
ANNALS OF INTERNAL MEDICINE (2009)
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
Thierry Poynard et al.
GASTROENTEROLOGY (2009)
Colchicine versus PEG-interferon alfa 2b long term therapy: Results of the 4 year copilot trial
N. H. Afdhal et al.
JOURNAL OF HEPATOLOGY (2008)
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Adrian M. Di Bisceglie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
Herbert L. Bonkovsky et al.
JOURNAL OF HEPATOLOGY (2007)
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial
Hans Orlent et al.
JOURNAL OF HEPATOLOGY (2006)
Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon
Bart J. Veldt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: A cohort study of 1249 patients
K Ikeda et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Treating viral hepatitis C: Efficacy, side effects, and complications
M. P. Manns et al.
GUT (2006)
Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy
M Moriyama et al.
LIVER INTERNATIONAL (2005)
Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line
S Matsui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2004)
Differential regulation of activator protein 1 activity by glycyrrhizin
CY Hsiang et al.
LIFE SCIENCES (2002)
Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma
H Kumada
ONCOLOGY (2002)
分享论文
